Pembrolizumab (new indication: cervical cancer with PD-L1 expression with a CPS ≥ 1, in combination with or without bevacizumab)

Subject:

• Active Sustance: Pembrolizumab
• Name: Keytruda®
• Therapeutic area: Cervical cancer
• Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

• Start: 01.08.2022
• Final decision by G-BA: 02.02.2023

Final decision:

1. Adults for whom pembrolizumab is the first-line therapy: 
   a1. Pembrolizumab used in combination with cisplatin and paclitaxel or carboplatin and paclitaxel: Indication for a considerable additional benefit
   a2. Pembrolizumab used in combination with any chemotherapy other than cisplatin and paclitaxel or carboplatin and paclitaxel:
   No additional benefit proved
    
2. Adults with first-line chemotherapy and for whom further antineoplastic therapy is being considered: No additional benefit proved